98 completed, 79 recruiting, 62 active not recruiting, 36 terminated. 201 Phase 2, 106 Phase 1, 45 Phase 3, 4 Phase 4, 3 Not applicable.
Follow obinutuzumab: new trials by email Literature Review of obinutuzumab trials Research Report on obinutuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Obinutuzumab in Systemic Sclerosis Obinutuzumab, Placebo - Systemic Sclerosis in Adults | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-11-01 | 2026-09-25 |
| Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma Glofitamab, Gemcitabine, Oxaliplatin - PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 40 | 2026-11-01 | 2026-10-22 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-10-22 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) obinutuzumab (RO5072759) - Lupus Nephritis | Phase 3 | Not yet recruiting | Zhao Minghui | 70 | 2026-09-10 | 2026-08-26 |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). Pirtobrutinib, Fludarabine, Cyclophosphamide - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 82 | 2026-09-01 | 2026-06-03 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
| A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 96 | 2026-07-22 | 2026-07-13 |
| Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) Orelabrutinib, Obinutuzumab, Venetoclax - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 39 | 2026-07-15 | 2026-07-22 |
| A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) Obinutuzumab Injection, Predniso(lo)ne - Minimal Change Disease (MCD) | Phase 2 | Recruiting | Medical University Innsbruck | 48 | 2026-07-13 | 2026-08-17 |
Showing 20 of 326. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (94) · Lymphoma, Follicular (51) · Lymphoma, Non-Hodgkin (36) · Lymphoma, Large B-Cell, Diffuse (32) · Lymphoma (31) · Lymphoma, Mantle-Cell (28) · Lymphoma, B-Cell, Marginal Zone (22) · Lymphoma, B-Cell (20) · Recurrence (18) · Neoplasms (11) · Leukemia (7) · Leukemia, B-Cell (7) · Lupus Nephritis (7) · Burkitt Lymphoma (6) · Leukemia, Hairy Cell (4)
Hoffmann-La Roche (58) · M.D. Anderson Cancer Center (13) · National Cancer Institute (NCI) (12) · Genentech, Inc. (10) · Ruijin Hospital (10) · German CLL Study Group (9) · Institute of Hematology & Blood Diseases Hospital, China (8) · Memorial Sloan Kettering Cancer Center (8) · The Lymphoma Academic Research Organisation (7) · BeOne Medicines (6) · The First Affiliated Hospital with Nanjing Medical University (6) · AbbVie (5) · Celgene (5) · Dana-Farber Cancer Institute (5) · Mayo Clinic (5)
United States (187) · France (67) · Italy (66) · Germany (62) · Spain (62) · China (61) · United Kingdom (49) · Australia (45) · Canada (36) · Poland (30) · Belgium (27) · Denmark (27) · Israel (26) · Brazil (25) · Austria (24)
Paula Cramer, Dr. med. (4) · Stephen E Spurgeon (3) · Barbara Eichhorst, MD, Prof. (2) · Christopher J Melani, M.D. (2) · Fernando Fervenza, MD (2) · Jae Park, MD (2) · Joseph M Tuscano (2) · Klaus Herfarth, MD (2) · Lei Zhang, MD (2)
PMID 38620092, PMID 31050355, PMID 37678236, PMID 40550489, PMID 32770353, PMID 33693991, PMID 26659915, PMID 30341058, PMID 31053601, PMID 32705923, PMID 34323957, PMID 34534514, PMID 34608724, PMID 35708885, PMID 38843483, PMID 40749164, PMID 22431570, PMID 22438256, PMID 23835715, PMID 23835718, PMID 23843495, PMID 24401022, PMID 25143487, PMID 25769620, PMID 26282650, PMID 26472752, PMID 27339738, PMID 27345636, PMID 28011903, PMID 28072473, PMID 28178345, PMID 28976863, PMID 29255066, PMID 29584548, PMID 29749403, PMID 29843792, PMID 29856692, PMID 30068505, PMID 30111609, PMID 30277102, PMID 30309758, PMID 30522969, PMID 30568174, PMID 30617197, PMID 30770362, PMID 30850381, PMID 30862645, PMID 30935953, PMID 31101489, PMID 31166681
2023 (16), 2014 (15), 2015 (14), 2016 (7), 2017 (6), 2018 (6), 2019 (6), 2009 (4), 2025 (4), P30CA033572 (4), P30CA093373 (2), P30CA138292 (2), U10CA180820 (2), U10CA180821 (2), U10CA180888 (2)